(Q35536471)

8 August 2017

title

BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112 (English)

1 reference

malignant pleural mesothelioma

8 August 2017

1 reference

1 reference

M F Muers

1

1 reference

8 August 2017

R M Rudd

2

1 reference

8 August 2017

M E R O'Brien

3

1 reference

8 August 2017

W Qian

4

1 reference

8 August 2017

A Hodson

5

1 reference

8 August 2017

M K B Parmar

6

1 reference

8 August 2017

D J Girling

7

1 reference

8 August 2017

British Thoracic Society Mesothelioma Group

8

1 reference

8 August 2017

language of work or name

English

0 references

publication date

1 February 2004

1 reference

8 August 2017

1 reference

8 August 2017

volume

59

1 reference

8 August 2017

issue

2

1 reference

8 August 2017

page(s)

144-148

1 reference

Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis

8 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1746929

The European mesothelioma epidemic

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1746929

Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1746929

Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1746929

A review of chemotherapy trials for malignant mesothelioma

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1746929

Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1746929

Continuing increase in mesothelioma mortality in Britain.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1746929

The new front line treatment for malignant pleural mesothelioma?

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1746929

Phase II study of vinorelbine in patients with malignant pleural mesothelioma

26 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/14760156

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/14760156

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/14760156

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1136/THORAX.2003.009290

1 reference

8 August 2017

1 reference

8 August 2017

1 reference